Change Control When a Model Is Updated or Retrained

Understanding Change Control in AI Model Lifecycle

Change control processes form the backbone of regulated AI implementation in pharmaceutical environments. When models undergo updates or retraining, organisations must maintain strict documentation and approval protocols. The primary purpose of these controls is to ensure that any modifications to AI systems do not compromise data integrity or regulatory compliance.

In pharmaceutical settings, where clinical decisions rely heavily on AI outputs, even minor changes require thorough evaluation.

The change control process begins with identifying potential modifications to existing models. This might occur when new clinical data becomes available, when regulatory requirements evolve, or when performance metrics indicate the need for improvement. For example, a machine learning model used for predicting drug interactions may require retraining when new clinical studies provide additional data points.

The change control board must evaluate whether these modifications represent minor updates or significant changes requiring full validation cycles.

Documentation and Approval Requirements

Effective change control requires detailed documentation of all modifications. When updating or retraining models, organisations must record the specific changes made, the rationale behind these modifications, and the impact on existing processes. The documentation should include technical specifications, data sources used for retraining, and validation results.

For instance, if a predictive model for clinical trial outcomes is updated using new patient demographics, the change log must specify exactly which demographic variables were included and how they affected model performance.

The approval process involves multiple stakeholders including data scientists, regulatory affairs specialists, quality assurance personnel, and clinical experts. Each reviewer must assess their particular domain of expertise. A clinical pharmacist might evaluate whether updated drug interaction predictions align with existing clinical knowledge.

Meanwhile, a data scientist would focus on statistical significance of performance improvements. The quality assurance team ensures that all documentation meets regulatory standards and that appropriate validation procedures have been followed.

• All changes must be documented in a centralised change control system
• Each modification requires formal approval from designated authority
• Impact assessments must be completed before implementation
• Training records must be maintained for personnel affected by changes

Implementation and Monitoring Protocols

The implementation phase requires careful coordination between technical teams and operational staff. Changes must be deployed gradually to minimise disruption to existing workflows. For example, when updating an AI system that supports clinical decision-making, organisations might implement the new model alongside the existing one for a period of time.

This allows clinical staff to compare outputs and ensures that any issues are identified before complete transition.

Monitoring protocols must be established to track the performance of updated models. Key performance indicators should be defined before deployment, including accuracy rates, processing times, and clinical outcome correlations. Regular audits should verify that the model continues to meet specified requirements.

If performance degrades or unexpected results occur, the change control process must be initiated to investigate and address issues.

The validation of updated models involves testing against established benchmarks and clinical data. This validation must demonstrate that the modified system maintains or improves upon previous performance levels. For instance, a model used for identifying adverse drug reactions must continue to detect known safety signals while potentially identifying new ones.

The validation process should include both retrospective analysis of historical data and prospective testing with new clinical cases.

Organisations must also consider the impact of model updates on existing data integrity measures. Updated models may process data differently, potentially affecting audit trails or data lineage. All changes must maintain traceability of data sources and processing steps.

Regular reviews ensure that the updated models continue to comply with data protection regulations and clinical governance requirements.

The final step involves communicating changes to all relevant personnel. Training sessions should explain the modifications and their implications for daily work processes. Documentation must be updated to reflect new procedures and protocols.

This communication ensures that clinical staff, data analysts, and other users understand how to properly utilise the updated AI systems.